Aerie Pharmaceuticals, Inc. (AERI) Financial Analysis & Valuation | Quarter Chart
Aerie Pharmaceuticals, Inc. (AERI)
AERIPrice: $15.25
Fair Value: 🔒
🔒score
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-... more
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and co... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Vicente Anido |
| IPO Date | 2013-10-25 | CAGR | — |
| Employees | 376 | Website | www.aeriepharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AERI chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.01B | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -40.77 |
| P/CF Ratio | -7.13 | P/FCF Ratio | — |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 105.41% | Gross Margin | 0.86% |
| Operating Margin | -0.23% | Profit Margin | -0.39% |
| ROE | -22.55% | ROA | -0.17% |
| ROCE | -0.15% | Current Ratio | 2.85 |
| Quick Ratio | 2.52 | Cash Ratio | 0.3 |
| Debt/Equity | -15.04 | Interest Coverage | -1.57 |
| Altman Z Score | — | Piotroski Score | — |